NCT07165717 A Real World Study of Respiratory Critical Disease.
| NCT ID | NCT07165717 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ming Zhong |
| Condition | ARDS (Acute Respiratory Distress Syndrome) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2019-03-01 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2019-03-01 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Acute Respiratory Distress Syndrome (ARDS) is a form of acute diffuse lung injury caused by various etiologies, which rapidly progresses to acute respiratory failure. It is characterized by a sudden onset and severe clinical course. Globally, ARDS affects approximately 3 million individuals each year, accounting for about 10% of admissions to intensive care units (ICUs). Due to the lack of specific pharmacological therapies, mechanical ventilation remains the mainstay of treatment. Therefore, identifying and analyzing prognostic factors for ARDS patients is of great significance for improving patient outcomes and reducing the incidence of poor prognosis.
Eligibility Criteria
Inclusion Criteria: * Patients with underlying diseases associated with high risk of ARDS, including but not limited to: sepsis, pneumonia, multiple trauma, pulmonary contusion, inhalation injury, massive blood transfusion, other high-risk conditions, or other factors causing excessive respiratory drive. * Patients meeting the inclusion criteria for a high-risk ARDS population. * Patients (or legal representatives) who have provided a signed and dated informed consent form. Exclusion Criteria: * Age under 18 years. * HIV infection. * Known immunodeficiency disorders (e.g., leukemia, common variable immunodeficiency, etc.). * History of solid organ or bone marrow transplantation. * Receiving treatment with G-CSF or GM-CSF. * Patients with a decision to withdraw from active treatment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07165717 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying ARDS (Acute Respiratory Distress Syndrome). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07165717 currently recruiting?
Yes, NCT07165717 is actively recruiting participants. Contact the research team at wang.yuxian@zs-hospital.sh.cn for enrollment information.
Where is the NCT07165717 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07165717 clinical trial?
NCT07165717 is sponsored by Ming Zhong. The trial plans to enroll 500 participants.